-- OneSource Specialty Pharma's (NSE:ONESOURCE, BOM:544292) partner Orbicular has received tentative approval from US Food and Drug Administration (US FDA) for a generic version of Ozempic (Semaglutide injection), according to a Tuesday filing to the Indian stock exchanges.
OneSource is the contract development and manufacturing organization (CDMO) partner for the complex peptide.
Orbicular led its product development and technical program, while OneSource supported the program as the CDMO partner, providing end-to-end manufacturing capabilities for the US market filing.
The collaboration will help to ensure a reliable commercial supply from OneSource's US FDA site in Bangalore, India.
The company's shares were down over 1% in recent trade.